US-based vaccine company Novavax has chosen its lead vaccine candidate for Covid-19, NVX-CoV2373. The company now plans to initiate its first in-human trial in mid-May; results of this combined Phase I/II study of 130 individuals are expected in July.
NVX-CoV2373 was created using Novavax’s proprietary nanoparticle technology and incorporates the company’s Matrix-M adjuvant, which enhances immune responses.
Novavax has been working on animal studies of several Covid-19 vaccine candidates with the support of University of Maryland School of Medicine associate professor Dr. Matthew Frieman and funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
Novavax CEO and president Stanley C. Erck noted: “Because of the tireless efforts and commitment of the Novavax team and our collaborators, we are preparing to initiate the NVX-CoV2373…trial in mid-May, weeks ahead of schedule.
“This progress demonstrates the ability of our recombinant nanoparticle technology to rapidly create vaccine candidates for emerging viruses like SARS-CoV-2 [, which causes Covid-19].
In addition, the performance of NVX-CoV2373 in multiple preclinical studies and testing gives us increased confidence in its potential to protect against Covid-19 disease.”